Contraindicated (one)pentobarbital decreases amounts of vandetanib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Steer clear of coadministration with powerful CYP3A4 inducers; these medications lessen publicity to vandetanib by nearly 40%.
pentobarbital will lower the extent or influence of ramelteon by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.
pentobarbital will minimize the extent or result of tamoxifen by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will lower the extent or outcome of diltiazem by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
pentobarbital will lower the extent or outcome of mavacamten by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
pentobarbital will reduce the extent or influence of doxorubicin liposomal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital and olopatadine intranasal each maximize sedation. Keep away from or Use Alternate Drug. Coadministration raises possibility of CNS melancholy, which can lead to additive impairment of psychomotor general performance and result in daytime impairment.
pentobarbital will lessen the extent or result of paclitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unknown.
pentobarbital will lower the extent or effect of triamcinolone acetonide injectable suspension by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Might bring about lack of virologic response and achievable resistance.
pentobarbital will lower the extent more info or outcome of zolpidem by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Mysterious.
pentobarbital will lower the extent or influence of atogepant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Keep an eye on Carefully. Advised atogepant dosage with concomitant use of strong or average CYP3A4 inducers is thirty mg or 60 mg qDay.
pentobarbital will minimize the level or outcome of midostaurin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Robust CYP3A4 inducers may perhaps reduce midostaurin concentrations causing decreased efficacy.
pentobarbital will lessen the level or outcome of armodafinil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unfamiliar.